S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 12.2 CHF -3.94% Market Closed
Market Cap: 129.6m CHF

Wall Street
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

Lowest
Price Target
30.3 CHF
148% Upside
Average
Price Target
30.6 CHF
151% Upside
Highest
Price Target
31.5 CHF
158% Upside
Santhera Pharmaceuticals Holding AG Competitors:
Price Targets
ONCO
Oncopeptides AB
294% Upside
KRYS
Krystal Biotech Inc
53% Upside
TECX
AVROBIO Inc
286% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
24% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
55% Upside
FHTX
Foghorn Therapeutics Inc.
150% Upside
ORY
Oryzon Genomics SA
164% Upside
BCAX
Bicara Therapeutics Inc
207% Upside

Revenue
Forecast

Revenue Estimate
Santhera Pharmaceuticals Holding AG

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 9%. The projected CAGR for the next 3 years is 60%.

9%
Past Growth
60%
Estimated Growth
Estimates Accuracy
11%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat

Net Income
Forecast

Net Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SANN's stock price target?
Price Target
30.6 CHF

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

What is Santhera Pharmaceuticals Holding AG's Revenue forecast?
Projected CAGR
60%

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 9%. The projected CAGR for the next 3 years is 60%.

Back to Top